These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9632273)

  • 1. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.
    Colby C; McAfee SL; Finkelstein DM; Spitzer TR
    Bone Marrow Transplant; 1998 May; 21(10):1005-10. PubMed ID: 9632273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.
    Piccirillo N; Sica S; Laurenti L; Chiusolo P; La Barbera EO; Sorà F; Leone G
    Bone Marrow Transplant; 1999 Jun; 23(12):1245-50. PubMed ID: 10414910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
    Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
    Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0.
    Sobrevilla-Calvo P; Zinser Sierra JW; Lara Medina FU; Acosta Barreda A; Calderón Flores E
    Rev Invest Clin; 2002; 54(1):51-6. PubMed ID: 11995407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
    Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
    Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
    Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
    Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study.
    Faucher C; Le Corroller AG; Chabannon C; Novakovitch G; Manonni P; Moatti JP; Nouyrigat P; Maraninchi D; Blaise D
    Bone Marrow Transplant; 1996 Apr; 17(4):533-6. PubMed ID: 8722350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
    Tarella C; Castellino C; Locatelli F; Caracciolo D; Corradini P; Falda M; Novarino A; Tassi V; Pileri A
    Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
    Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
    Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
    Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
    Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
    de Azevedo AM; Nucci M; Maiolino A; Vigorito AC; Simões BP; Aranha FJ; Tabak DG; Voltarelli J; de Souza CA
    Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults.
    Ojeda E; Garcia-Bustos J; Aguado M; Arrieta R; Quevedo E; Yuste VJ; Canales M; Hernandez-Navarro F
    Bone Marrow Transplant; 1999 Sep; 24(6):601-7. PubMed ID: 10490724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
    Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
    Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
    Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
    Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.